Online forums have markedly altered how patients, caregivers, and healthcare professionals communicate and connect. Even when miles apart, individuals can establish supportive relationships, share experiences and information, and sometimes simply vent. Bionews Services, a leading online health, science, and research publication company, has been introducing its own…
Inflammatory bowel disease (IBD) increases the risk of developing idiopathic pulmonary fibrosis (IPF), particularly in male patients with Crohn’s disease, a large-scale population study shows. The study, “Increased Risk of Idiopathic Pulmonary Fibrosis…
Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev (nintedanib) treatment in patients with idiopathic pulmonary fibrosis (IPF), a study has found. These results also suggest that lower performance status and a full starting dosage are risk factors…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Impaired autophagy — cells’ self-cleansing process — in the lungs’ epithelial cells may activate their epithelial-mesenchymal transition (EMT), a process crucial to the progression of fibrosis, according to a new study. The finding suggests that therapies targeting EMT may help halt fibrosis in idiopathic pulmonary fibrosis (IPF). The study, “…
N115, EmphyCorp‘s investigational non-steroidal nasal spray for the treatment of interstitial lung diseases (ILDs), has completed a Phase 3 clinical trial requested by the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) in patients with pulmonary fibrosis (PF). EmphyCorp’s proprietary…
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the analysis were published in the journal Advances In Therapy in an article titled, “Cardiovascular Risks,…
People with idiopathic pulmonary fibrosis (IPF) and right heart dysfunction may benefit more from a therapy combining Ofev (nintedanib) with sildenafil than from Ofev alone in terms of cardiac health, according to data from a Phase 3 study. The study, “Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary…
The natural product tannic acid has anti-fibrotic effects on cultured human lung fibroblasts and in an in vivo idiopathic pulmonary fibrosis (IPF) mouse model by reducing signals from TGF-beta receptors, a new study has found. The study, “…
At-home use of wearable physical activity trackers and portable spirometry devices may offer a feasible way of evaluating people with idiopathic pulmonary fibrosis (IPF) taking part in clinical trials, a small study suggests. These findings were reported in “Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis,”…
Get regular updates to your inbox.
